Literature DB >> 33097622

Current situation of carboplatin desensitisation protocols in the hospitals of Spain.

Rocío Vázquez Sánchez1, Javier Sánchez-Rubio Ferrández2, Damián Córdoba-Díaz3, Manuel Córdoba-Díaz3, Raúl Díez-Fernández2, Teresa Molina-Garcia2.   

Abstract

Desensitisation protocols allow the continuation of treatment in patients who have presented hypersensitivity reactions. Carboplatin desensitisation solutions are usually prepared in the chemotherapy centralised units of hospital pharmacies and they are diluted under the established concentration limit to guarantee the stability of the preparation. An online survey was sent to hospital pharmacies, inquiring about local desensitisation protocols: reasons for use of desensitisation protocols, the protocols used and the stability given to carboplatin solutions. An important variability among the hospitals in carboplatin desensitisation practice was detected. Six different carboplatin desensitisation protocols were described and discordance with the storage period of the carboplatin solutions was observed. The lack of consensus on which protocol must be followed and data supporting the stability of the diluted product, contribute to distrust of carboplatin desensitisation protocols. Although the efficacy and safety of carboplatin desensitisation protocols has been widely demonstrated, many professionals still have concerns. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  carboplatin; desensitisation; drug stability; hypersensibility; survey

Year:  2019        PMID: 33097622      PMCID: PMC7856132          DOI: 10.1136/ejhpharm-2018-001746

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  10 in total

1.  Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.

Authors:  Marisa Navo; Anuradha Kunthur; Martina L Badell; Larry W Coffer; Maurie Markman; Jubilee Brown; Judith A Smith
Journal:  Gynecol Oncol       Date:  2006-06-22       Impact factor: 5.482

Review 2.  Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity.

Authors:  Ticha Limsuwan; Mariana C Castells
Journal:  Expert Opin Drug Saf       Date:  2010-01       Impact factor: 4.250

3.  A modified protocol for rapid desensitization to chemotherapy agents.

Authors:  Carmen Vidal; Paula Méndez-Brea; Sara López-Freire; Beatriz Bernárdez; Maria-Jesús Lamas; Margarita Armisén; Virginia Rodríguez; Ildefonso Luna; Mónica Castro-Murga
Journal:  J Allergy Clin Immunol Pract       Date:  2016-06-24

Review 4.  Outpatient desensitization in selected patients with platinum hypersensitivity reactions.

Authors:  David M O'Malley; Monica Hagan Vetter; David E Cohn; Ambar Khan; John L Hays
Journal:  Gynecol Oncol       Date:  2017-04-11       Impact factor: 5.482

Review 5.  Rapid desensitization of hypersensitivity reactions to chemotherapy agents.

Authors:  Mariana Castells
Journal:  Curr Drug Saf       Date:  2006-08

Review 6.  Platinum hypersensitivity and desensitization.

Authors:  Shingo Miyamoto; Rika Okada; Kazumichi Ando
Journal:  Jpn J Clin Oncol       Date:  2015-06-07       Impact factor: 3.019

7.  Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.

Authors:  Mariana C Castells; Nichole M Tennant; David E Sloane; F Ida Hsu; Nora A Barrett; David I Hong; Tanya M Laidlaw; Henry J Legere; Samridhi N Nallamshetty; Ross I Palis; Jayanti J Rao; Suzanne T Berlin; Susana M Campos; Ursula A Matulonis
Journal:  J Allergy Clin Immunol       Date:  2008-05-27       Impact factor: 10.793

8.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Authors:  M K B Parmar; J A Ledermann; N Colombo; A du Bois; J-F Delaloye; G B Kristensen; S Wheeler; A M Swart; W Qian; V Torri; I Floriani; G Jayson; A Lamont; C Tropé
Journal:  Lancet       Date:  2003-06-21       Impact factor: 79.321

Review 9.  Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century.

Authors:  M C Castells Guitart
Journal:  J Investig Allergol Clin Immunol       Date:  2014       Impact factor: 4.333

10.  Stability of carboplatin infusion solutions used in desensitization protocol.

Authors:  R Vázquez-Sánchez; J Sánchez-Rubio-Ferrández; D Córdoba-Díaz; M Córdoba-Díaz; T Molina-Garcia
Journal:  J Oncol Pharm Pract       Date:  2018-05-10       Impact factor: 1.809

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.